Xtampza ER Warnings Can't Be Hidden Behind Table And Chairs, US FDA Tells Collegium

The US FDA's Office of Prescription Drug Promotion (OPDP) has taken Collegium Pharmaceutical Inc. to the woodshed in the office's first untitled letter and tangible enforcement action of 2018, which says the warning information for Xtampza ER (oxycodone extended-release) were visibly obstructed by a table and chair at an exhibit booth.